Genome-wide association scans allow millions of singlenucleotide polymorphisms (SNPs) to be genotyped or imputed and studied simultaneously using hypothesisfree agnostic approaches 1,2 . Although single genomewide association studies (GWASs) have identified many variants associated with complex diseases, these variants currently explain little of the risk variability for most diseases. Genetic effects due to common alleles are small, and detection of signals requires large sample sizes [3] [4] [5] [6] . As single GWASs are underpowered, meta-analysisthe statistical synthesis of information from multiple independent studies -increases power and reduces false-positive findings. Also, the techniques developed for meta-analysis can use summary data, diminishing the limitations that are imposed by restrictions on sharing individual-level data. Therefore meta-analysis has become a popular approach for the discovery of new genetic loci for common diseases and phenotypes. Most genetic risk variants discovered in the past few years have come from large-scale meta-analyses of GWASs 7 . Several hundred GWAS meta-analyses have already been published. In the period between the beginning of 2009 and 15 th June 2012, 139 of these meta-analyses had sample sizes in the discovery phase exceeding 10,000 participants 8 . These efforts have dramatically increased the yield of discovered and validated genetic risk loci, thus making a case that the manpower and time required for such a design are justified. Large meta-analyses may continue to increase the yield of loci in proportion to total sample size 9, 10 .
Genome-wide association scans allow millions of singlenucleotide polymorphisms (SNPs) to be genotyped or imputed and studied simultaneously using hypothesisfree agnostic approaches 1, 2 . Although single genomewide association studies (GWASs) have identified many variants associated with complex diseases, these variants currently explain little of the risk variability for most diseases. Genetic effects due to common alleles are small, and detection of signals requires large sample sizes [3] [4] [5] [6] . As single GWASs are underpowered, meta-analysisthe statistical synthesis of information from multiple independent studies -increases power and reduces false-positive findings. Also, the techniques developed for meta-analysis can use summary data, diminishing the limitations that are imposed by restrictions on sharing individual-level data. Therefore meta-analysis has become a popular approach for the discovery of new genetic loci for common diseases and phenotypes. Most genetic risk variants discovered in the past few years have come from large-scale meta-analyses of GWASs 7 . Several hundred GWAS meta-analyses have already been published. In the period between the beginning of 2009 and 15 th June 2012, 139 of these meta-analyses had sample sizes in the discovery phase exceeding 10,000 participants 8 . These efforts have dramatically increased the yield of discovered and validated genetic risk loci, thus making a case that the manpower and time required for such a design are justified. Large meta-analyses may continue to increase the yield of loci in proportion to total sample size 9, 10 .
As GWAS meta-analysis has become so popular and as new waves of even more extensive data are accumulating from sequencing efforts, it is timely to review the meta-analysis methods that have successfully been applied so far and also to highlight novel approaches that may be useful for the discovery of new variants. We cover the main models along with their extensions and the inferential tools that are being used, providing guidance for the most appropriate methods in particular situations. Moreover, we address issues of heterogeneity and describe methodological approaches that take into account heterogeneity introduced by various sources, such as phenotype definition, different ancestral groups, different genotyping platforms or imputation software. Given that research is increasingly shifting towards lowfrequency and rare variants, we also describe methods for the meta-analysis of these variants.
Meta-analysis stages Previous reviews have described in detail the organizational stages of a GWAS meta-analysis 7, 11, 12 , and only a brief overview is provided here (FIG. 1) . In BOX 1,  we provide a more detailed description of different steps of meta-analysis, including setting up an analysis plan, dealing with heterogeneity, data storage, prioritization of variants for follow up and other secondary analysis [13] [14] [15] [16] [17] [18] [19] . Some successful high-profile consortia for which workflows can be followed and for which useful material describing their operations can be downloaded are summarized in TABLE 1.
Summary data
Data that present summary statistics of a population and are used in meta-analysis approaches without granting access to individual-level data.
Imputation
In genetics, the inference of genotypes of markers that have not been directly genotyped by making use of information from haplotype reference panels such as the HapMap or the 1000 Genomes panels.
Genome-wide significance
The significance threshold for rejecting the null hypothesis in genome-wide association studies.
Minor allele frequency (MAF) . The frequency of the less common allele of a polymorphic locus. It has a value that lies between 0 and 0.5 and can vary between populations.
Models for data synthesis
There are several approaches for GWAS meta-analysis. Here, we discuss methods that have been widely applied so far and alternative or new methods that have been proposed. For each model, issues such as weighing, power and ability to detect heterogeneity are discussed. TABLE 2 presents commonly used bioinformatics tools and software [20] [21] [22] [23] . P values and Z scores. Meta-analysis methods based on P values were widely used in different scientific fields until the 1980s but then became unpopular and were almost abandoned in biomedical sciences. This was because they suffered from several limitations, such as an inability to provide a summary effect and difficulties in addressing heterogeneity issues. The best known method of this type is Fisher's approach, but over a dozen other methods exist for combining P values in the traditional meta-analysis literature 24 , although the large majority of these has never been applied with P values in the genome-wide significance range. In these approaches, the null hypothesis is that the true effect is null in each of the combined data sets (the alternative hypothesis is that there is a non-null association in at least one data set). The major disadvantage of P values meta-analysis is that it cannot provide an overall estimate of effect size. Moreover, between-data-set heterogeneity cannot be assessed, and there is disagreement on the optimal weighting of studies. Furthermore, combining P values may be spurious when the direction of effects in the combined studies is not consistent.
A closely related approach to Fisher's method is based on Z scores 24 . As Fisher's method is based on the average of -log(P i ) across all studies (where P i is the P value of the i th study) and as the Z scores method is based on the average of the Z i values, these two approaches are highly correlated. One advantage of the Z score approach is that it takes into account the direction of the effect, and it is rather straightforward to introduce weights. A review has shown that metaanalysis of Z scores and P values (obtained using Fisher's method) has been applied in 14% and 3% of the published GWAS meta-analyses, respectively 25 . Both P values and Z scores meta-analysis might be useful tools for the synthesis of low-frequency variants (that is, those with a minor allele frequency (MAF) of 1-5%) or rare variants (that is, those with an MAF of <1%) when the association is based on tests that provide P values or Z test statistics rather than effect estimates 19, 26 (see later for a discussion of methods for low-frequency and rare variants).
Fixed effects.
Fixed effects meta-analysis is the most popular approach for synthesizing GWAS data and the most powerful approach for prioritizing and discovering phenotype-associated SNPs 27 . Fixed effects metaanalysis assumes that the true effect of each risk allele is the same in each data set. This is a rather tenuous assumption, but fixed effects models have the major advantage of maximizing discovery power compared to random effects models (see below) 28 . There are different models for fixed effects meta-analysis, but the inverse variance weighting 29 , in which each study is weighted according to the inverse of its squared standard error, is predominantly used 7 . Another common method used in genetics is the Cochran-Mantel-Haenszel approach, which provides almost identical results to the inverse variance weighting method 24 . All bioinformatics tools that have been developed for GWAS meta-analysis carry out inverse variance meta-analysis [20] [21] [22] [23] .
Random effects. By far the most popular estimator of the between-study variance for the random effects approach is the DerSimonian and Laird estimator 30 , but many others approaches also exist (for example, Sidik-Jonkman, Hedges-Vevea, Hunter-Schmidt and Schuster methods). The DerSimonian and Laird approach may give less robust results with small numbers (for example, rare variants) 24, 31, 32 . Random effects models are not used in discovery efforts owing to far more limited power than fixed effects models; however, random effects models are more appropriate than fixed effects models when the aim is to consider the generalizability of the observed association and estimate the average effect size of the associated variant and its uncertainty across different populations: for example, for predictive purposes 28, 33 . Nature Reviews | Genetics 
Hardy-Weinberg equilibrium
A principle stating that the genetic variation in a population will remain constant from one generation to the next in the absence of disturbing factors.
Bayesian approaches
Fully probabilistic methods for describing models, parameters and data. They are so called because extensive use is made of Bayes' theorem to compute the probability distribution of model parameters given the experimental data.
Some new random effects methods have been proposed for improving discovery power in the presence of between-study heterogeneity in effect sizes. Han and Eskin 34 assume that there is no heterogeneity under the null hypothesis, in contrast to the traditional random effects models. Their statistic can be decomposed into two parts, one that is equal to the fixed effects statistic and another that is equal to the test statistic for heterogeneity. Further empirical validation of loci discovered by this method would be useful.
Optimal weights. Intuitively, it makes sense that studies with more data should count more (that is, have a larger weight) in the meta-analysis calculations, but the definition of weights depends on the statistical model used. The optimal weight for meta-analysis is the inverse variance weighting 35 . The favourable properties of such weighting in GWAS meta-analysis are well-known for initial screenings and discovery 28 . For imputed SNPs, simulations show that the optimal weight is proportional to the inverse variance and the expected value of the effect estimate 36 , but the inverse variance modelling scheme approximates the optimal weights well. Other weights derived from score statistics can have practical advantages when only P values and direction of effects have been provided, and they might be easier to interpret when there are differences with respect to covariates or definitions of the phenotypes that are modelled. For small effect sizes, the optimal weights from score statistics have essentially the same power as inverse variance weighting 37 .
Bayesian meta-analysis. Some consortia have applied Bayesian approaches for GWAS meta-analyses. Specifically, the Wellcome Trust Case Control Consortium has used the Bayes factor 38 , whereas the Coronary Artery Disease Consortium has presented results as posterior probabilities that a variant is null 39 .
Box 1 | Stages in a GWAS meta-analysis
Setting up an analysis plan Each genome-wide association study (GWAS) meta-analysis initiative should be based on strong collaborative agreements and should be carefully designed and organized. An analysis team should design and draft a detailed plan that explicitly describes all of the steps of the anticipated analysis. Independent performance of some core statistical analyses by at least two analysts and using different software is not uncommon and may also allow for cross-verification and quality checks of processes and results. The analysis plan should be adopted by all teams, which should try to avoid deviations that introduce unnecessary between-study heterogeneity.
Dealing with heterogeneity
Despite careful planning to avoid heterogeneity, sometimes differences are inevitable, even in prospective designs: for example, when some samples have a family structure or when designs include extreme values 13 . Also, differences in phenotype definition may affect the estimated magnitude of the genetic effects, a factor that needs to be considered in terms of optimizing power for discovering new associations 6 . Ideally, phenotype definitions should be standardized according to stringent definitions applied in all data sets; if perfect standardization is impossible, participating teams should decide what kind of harmonization of definitions is desirable and feasible 14 . Inclusion and exclusion criteria of subjects and variants should be described in detail. Popular exclusion thresholds are >5% missing data, P < 10 −5 for Hardy-Weinberg equilibrium and quality index <0.3 for imputation metrics (BOX 2 summarizes the challenges of the imputation efforts using 1000 Genome Project panels 2, 15 ). Also, strand issues should be considered during quality control for the proper alignment of the alleles. Most GWAS meta-analyses to date focus on common variants and exclude variants with minor allele frequency <1%. However, this is likely to change as low-frequency and rare variants become the focus of interest. Statistical methods that account for between-study heterogeneity introduced by various sources are described in the main text.
Data storage
Data storage is an important aspect of meta-analysis as the individual-level data collected by each partner and also single participants' genotypes should be kept secured and unidentifiable. Most collaborative meta-analyses use online storage options to deposit summary data, giving access to members of the analysis team. This enables the partners to retain control of individual-level primary data. In most settings, summary data are statistically as efficient for meta-analysis as individual-level data 16 . The major drawback of working with summary data comes when more detailed investigations are required, such as conditional analyses, gene-gene interactions or adjusted analyses.
Prioritization of variants for follow-up and other secondary analyses
A GWAS meta-analysis may suggest variants to test in additional follow-up efforts. Prioritization of variants should follow rules that are pre-specified in the analysis plan. These typically include thresholds of statistical significance, but additional information may also be incorporated (for example, biological plausibility, evidence from other GWASs and other meta-analyses in the same field, text-mining-based methods or information on pathways 17 ). The analysis plan should also specify how to choose among potentially multiple correlated variants based on linkage disequilibrium considerations.
When a variant passes the agreed level of genome-wide significance (typically set at P < 5 × 10 −8
), other secondary analyses might follow to assess the importance and the mode of action of the variant. For example, conditional analysis may be carried out for: other variants in the vicinity; adjustments for other traditional risk factors; gene-gene, gene-environment or protein-protein interactions; and diverse functional tests that may be carried out in silico, in vitro or in vivo 19 .
Bonferroni correction
A method to counteract the problem of multiple comparisons. It is the simplest and most conservative approach to control for type I error.
Type I error
The probability of rejecting the null hypothesis when it is true. For genetic association studies, type I errors reflect false-positive findings of associations between allele or genotype and disease.
Linkage disequilibrium
The nonrandom association of alleles of different linked polymorphisms in a population.
Bayesian methods have also been developed to characterize the best fitting inheritance model for variants emerging from GWAS meta-analyses 40 , to characterize the polygenic architecture of complex traits for which there are thousands of top SNPs 41 and for multivariate methods (see relevant section below). Bayesian models are straightforward and intuitive, and the models used (for example, fixed, random effects) can be similar to the models used in the frequentist approaches described above. However, Bayesian models may depend on assumptions made about the prior distributions of parameters of interest, and their genome-wide implementation can become computationally intensive.
Inferential tools and their interpretation P values and genome-wide significance thresholds. The most common measure used for flagging a SNP as 'noteworthy' is the P value 42 . The selection of the most suitable genome-wide significance threshold should take into account the multiplicity of comparisons carried out. Some early GWASs used a threshold of P ≤ 10 −7 , but the current practice, in which more SNPs are actually typed and the imputation quality is higher, accepts a threshold of P ≤ 5 × 10 −8 as reaching genomewide significance. This roughly corresponds to a simple Bonferroni correction to maintain a 5% genome-wide type I error rate that is based on an estimated burden of 1 million independent comparisons for common sequence variation 18, 43 . However, a study has shown that associations with borderline genome-wide significance (that is, P ≥ 5 × 10 −8 and P ≤ 10 −7 ) are successfully replicated 73% of the time when additional data are accumulated 44 . The most suitable genome-wide significance threshold may vary for different populations, SNPs, MAFs, linkage disequilibrium (LD) patterns, arrays or different types of genetic data, but the differences are not major. For example, for populations with lower LD, such as Africans, stricter thresholds would be most appropriate 45 .
Bayes factors. The Bayes factor 46 represents the ratio of the probability of the data under the null hypothesis, H 0 , to the probability of data under the alternative hypothesis. Following the Bayes theorem, the posterior odds of H 0 = Bayes factor × prior odds of H 0 . Bayes factor and P values will often provide similar rankings for MAFs in the range 0.1-0.5 (REF. 47 ). However, differences can be observed for SNPs with low MAFs, which will be more often assessed as next-generation sequencing data become more commonly used in GWASs 47 .
Q values (false discovery rate). Q values and false discovery rate (FDR) 48 are very popular in 'omics' fields such as gene expression profiling, in which multiplicity issues are prominent, but surprisingly they have rarely been used in GWASs and meta-analyses thereof. The FDR estimates the proportion of associations that are seemingly discovered but are nevertheless expected to be false positives. The Q value is the minimum FDR that can be attained when declaring an association. Q values can be calculated for a list of P values using publicly available software called QVALUE 48 . An efficient process for selecting top SNPs using false-discovery rates following by further screening with least absolute shrinkage and selection operator (LASSO) regression has been proposed 49 .
Reliability of signals from imputed genotypes.
Imputation can allow data to be combined from studies using different genotyping platforms. Imputation is 
Population stratification
The presence of several population subgroups that show limited interbreeding. When such subgroups differ both in allele frequency and in disease prevalence, this can lead to erroneous results in association studies.
Principal components
A composite variable that summarizes the variation across a larger number of variables, each represented by a column of a matrix.
problematic for polymorphisms with low MAFs and those without at least modestly linked markers. Often, imputed variants with MAFs <5% (and certainly those with MAFs <1%) are disregarded and excluded from the analysis 11 . Imputation quality is usually measured by imputation accuracy. For most SNPs, imputation algorithms implemented in IMPUTE, MACH, MINIMAC or BEAGLE have very high imputation accuracy provided that the study population is similar to the reference population in terms of LD patterns and MAFs [50] [51] [52] . A metric to estimate the imputation quality is r 2 , which is the ratio of the empirical variance of the imputed genotypes to the expected variance given the imputation estimate of the MAF. However, with lowfrequency SNPs, the use of r 2 to evaluate the quality of the imputation can be misleading. Reliability of imputation in these cases can be assessed with imputation quality score (IQS) 53 . IQS takes chance agreement into account and thus controls for allele frequencies. Metaanalytical methods that take into account the errors in imputation by weighing not only in the inverse variance of each study but also in the accuracy of the imputed genotypes have been developed in each study; in some simulation studies, they may slightly outperform standard meta-analytical approaches 54 , but this is not seen by all authors 37 . Challenges for imputations using panels from the 1000 Genomes Project are presented in BOX 2.
Dealing with heterogeneity Phenotype-based heterogeneity. GWASs have been less successful for diseases in which phenotypes have been more difficult to define and to standardize, such as cognitive traits and mental-health-related diseases 55 , behavioural traits 56 and osteoarthritis 57, 58 . Evidence from other fields, such as obesity, also suggests that the establishment of associations may be dependent on phenotype definition 59 and that variability in definitions may cause heterogeneity in effect size or even spurious associations 60 . In some cases, harmonization of different phenotype definitions 61, 62 is possible, whereas in other situations this may not be feasible: for example, if phenotypes have already been collected and it is not possible to go back and remeasure them. The process must balance the need to augment the sample size (to increase power for gene discovery) with the likelihood of increased heterogeneity, which dilutes the average genetic effect and thus leads to loss of power 6 . Methods have been proposed to improve power in the presence of heterogeneous traits 63, 64 but have not been extensively used.
Ancestry-based heterogeneity. Synthesizing data from populations of different ancestry may increase the observed heterogeneity. The agnostic GWAS approach usually captures common markers that are likely to be in linkage only with the functional or causative culprits; the most strongly associated SNP may not be the functional or the causative variant. An assessment of GWAS-discovered variants shows modest correlation in MAF of the variants between ancestries and different genetic effects in different ancestries 65 . However, consistency across different ancestries may be higher for some common diseases 66 . A proposed transethnic meta-analysis approach takes into account the similarity in allelic effects between the most closely related populations while allowing for heterogeneity between more diverse ethnic groups 67 ; this approach may occasionally improve power to detect a novel association and localize causal variants 67 .
Other sources of heterogeneity. There are several other sources that can introduce heterogeneity in meta-analysis of genetic data. Population stratification may exist even in populations that are assumed to be fairly homogeneous: for example, Europeans [68] [69] [70] . One study showed different stratification patterns in the UK population for rare and low-frequency variants 71 . Adjusting for principal components can handle heterogeneity for common variants, but additional methods are required to address stratification issues for rare variants 71 . Heterogeneity can also be introduced by using different genotyping platforms, imputation software or qualitycontrol criteria across studies 33 . Gene-gene interactions and gene-environment interactions with differential non-genetic environmental exposures across different populations may also introduce heterogeneity -see below for a discussion of meta-analysis of joint estimation of interaction effects.
Finally, sex differences may induce heterogeneity, and some studies suggest differential genetic effects with respect to sex for many common variants 72 , although this has not been borne out in other large-scale empirical studies 73 . Methods that optimize power for metaanalysis of sex-specific GWASs have been proposed 74 . Statistical metrics of heterogeneity. Typical heterogeneity metrics that are extensively used in GWAS metaanalyses are Cochran's Q statistic and I 2 . Cochran's Q statistic follows a χ 2 distribution with k-1 degrees of freedom, where k is the number of studies and is typically considered to be significant at α = 0.10 (where α is the type I error) 35 . However, the test is often underpowered when there are few studies (for example, <20), which is a common scenario in GWAS meta-analysis. The power of the Q statistic can be estimated 75 , and it can be used in the estimation of the posterior odds of heterogeneity in a Bayesian framework 76 . Q is also used in the estimation of the between-study variance; the ratio of the effect size over τ (which is defined in BOX 3) offers an estimate of how big the effect is against the typical variability seen across studies and populations. Finally, I 2 quantifies the heterogeneity by measuring the amount of heterogeneity that is not due to chance 77 . It ranges from 0-100% and is considered low, moderate, large and very large for values 0-25%, 25-50%, 50-75% and >75%, respectively 78 . Statistical properties of heterogeneity metrics are presented in BOX 3.
Other extensions Cross-phenotype meta-analysis. Cross-phenotype metaanalysis (CPMA) aims to detect multiple associations at a single marker across different diseases that may share a common genetic background or that involve a common biological process, such as autoimmunity 79 . CPMA assumes that the P values used for the individual traits come from different non-overlapping cohorts; as such, it cannot be applied in the case of large consortia that investigate many phenotypes but usually share the same control samples 79 . Modest overlap of the control samples (<50%) is tolerable, but large overlaps erode the power of this statistic. CPMA has been applied in the study of immune-mediated and autoimmune diseases; of 107 previously identified variants across seven diseases, almost half were shared across diseases 79 . The CPMA statistic is agnostic to the direction of effect in each disease and can detect markers for at least some, but not necessarily all, phenotypes. It has one degree of freedom as it measures a deviation in P value behaviour instead of testing all possible combinations of diseases for association to each SNP, and therefore provides high power to reject the null hypothesis. However, power comes at the price of not knowing to which phenotypes the marker is associated, thus requiring further evidence.
Exploratory cross-phenotype checks.
A common practice in many GWAS meta-analyses is to carry out crossphenotype checks. Here, SNPs that have been identified as being significantly associated with one phenotype are also tested for association with other phenotypes in the same or other consortia. Typically, related phenotypes are examined: for example, SNPs that have been found to be associated with coronary artery disease may be specifically tested for association with phenotypes that represent diverse components of the metabolic syndrome 80 . Such checks could offer interesting insights about the pathophysiological paths implicated. The risk is that these analyses are exploratory, and thus their reporting may be less than comprehensive, potentially leading to selective reporting bias.
Joint meta-analysis for main and interaction effects.
Main effects analysis may fail to identify additional susceptibility loci that interact with environmental factors GCTA, genome-wide complex trait analysis; GWAS, genome-wide association study.
Main effects
The effects of a variable assuming no dependency or conditionality of other variables.
Bivariate meta-analysis
Joint synthesis of two phenotypes by using their correlation.
if the genetic effects for distinct levels of an environmental exposure are not investigated. A method of joint analysis of SNP and SNP-environment interaction coefficients has been proposed using a multivariate approach that provides confidence intervals for the two estimates and a test of homogeneity across samples. This method performs better when both main and interaction effects are present
81
, when joint meta-analysis may have a potential power gain of over 50% compared with classical meta-analysis 82 . Application of joint metaanalysis is hampered by a lack of sufficient environmental exposure data in most genetic data sets.
Meta-analysis of multiple correlated phenotypes.
Consideration of several correlated phenotypes together in the same studies can boost power 83 . Different methods for meta-analyses of correlated phenotypes have been proposed 84, 85 . The principle is that of bivariate meta-analysis, which is adapted for handling the correlation between outcomes 84 . The method can be applied both to binary and to continuous outcomes. One of the drawbacks is that individual-level data might be needed; however, methods for calculation of the covariance between two correlated effect sizes from summary data have also been proposed 85 . These approaches have not been applied yet in GWAS data sets, but they may offer the advantage of increased rigor to exploratory crossphenotype checks within the same consortium.
Meta-analysis of multiple correlated variants. This multivariate approach is also known as multipoint, multi-locus, multi-marker or joint multiple-SNP analysis. The causal variant may not necessarily emerge as the top SNP in a GWAS meta-analysis, and there may be multiple causal variants at the same locus, each independently contributing to genetic association with the phenotype 86, 87 . Conditional analysis has been used as a tool to detect secondary independent signals at a locus, but individual-level data are required, which are usually unavailable for large-scale meta-analysis of GWASs.
An approximate conditional approach using summary data from a meta-analysis and LD correlations between SNPs estimated from a reference sample (here, a subset of the meta-analysis sample) was successfully applied in a meta-analysis for height and body mass index 88 . This method identified 36 loci with multiple associated variants for height adding 49 additional SNPs on top of the already known variants. In this approach, a genome-wide stepwise selection procedure selects SNPs on the basis of conditional P values and estimates the joint effects of all selected SNPs after the model has been optimized. The method assumes that the reference sample is from the same population as the samples from which the genotype-phenotype associations are estimated (that is, that linkage correlation estimates in the reference sample are unbiased). Simulations show that P values from this approximate approach are consistent with those from conditional analysis using individuallevel data 88 . A reference sample of at least 2,000 is required to estimate linkage correlations with little error.
Mendelian randomization in GWAS meta-analysis.
Mendelian randomization entails the use of genetic variants as proxies ('instrumental variables') for modifiable or environmental exposures under investigation 89 . Meta-analysis methods have been proposed for Mendelian randomization studies 90 . Meta-analysis can help to bypass the problem that most genetic variants used as instrumental variables have small effects with large uncertainty in small studies, and thus they also leave large uncertainty about the presence or absence of causal relationships. For example, a large Mendelian randomization study based on a GWAS meta-analysis managed to demonstrate conclusively that high-density lipoprotein (HDL) is not causally related to coronary artery disease, as variants that affect specifically HDL levels do not have an impact on coronary artery disease risk 91 .
Sequence data and low-frequency variants Low event rates and zero counts. As discussed above, it has been common practice in GWAS meta-analyses to exclude low-frequency and rare variants. The main reason for these exclusions was related to imputation and genotyping quality, but this practice also worked as a safety net for avoiding false-positive or other spurious findings that would mostly be statistical artefacts. This situation is now changing as projects such as the 1000 Genomes Project 15 and the UK10K, along with the advent of next-generation sequencing technologies 92 ,
Box 2 | Challenges for imputation using data from the 1000 Genomes Project
Genotype imputation has widely been used in meta-analysis of genome-wide association studies (GWASs). In the first generation of GWASs, most imputation analysis used panels from Phase 2 of the International HapMap project, which contained a total of 210 unrelated individuals with ancestry from West Africa, East Asia and Europe. The 1000 Genomes Project 15 has now extended this resource by applying whole-genome shotgun sequencing to an even larger number of individuals (2,500) sampled from around 25 different locations. Direct sequencing can identify variants that are not represented on the genotyping arrays that were used in the HapMap Project and therefore can include more reference panels with most of the new variants occurring at low population frequencies. However, this might create enormous databases that require more exhaustive computer power to be analysed.
For original single-nucleotide polymorphism (SNP) sets from the 1000 Genomes Project, the estimated imputation quality criteria should be treated with caution and should be more conservative, given that early haplotype sets were of lower quality. However, in mid-2012, the 1000 Genomes Project released a powerful reference panel known as 'Phase I v3'. Different approaches for imputing the panels are proposed from publicly available imputation software such as IMPUTE2, MACH and BEAGLE.
will facilitate the study of low-frequency and rare variants. This translates, however, to larger sample size requirements to robustly identify associations involving variants in these classes that have modest effects. The problem is magnified for uncommon phenotypes. Asymptotic assumptions may not hold for rare variants or even low-frequency ones. Zero counts in 2 × 2 tables may become a common scenario. Typically used solutions use continuity corrections: for example, adding 0.5 to all four cells of the 2 × 2 table. However, most meta-analysis methods, including inverse variance fixed effects, DerSimonian and Laird random effects, and MantelHaenszel, perform poorly with such corrections to zero counts. The Peto method seems the least biased 93 , but this method is also problematic when the two groups that are compared are unequal in terms of observed events and sample sizes. Other approaches besides continuity corrections may be considered (for example, arcsine transformation 94 ), but there is no empirical evidence yet that relates to their application in genetics. Mega-analysis (which is the pooling of all individuallevel data from all studies into a common single data set; see below) may also be useful, but in this case, analyses need to account carefully for ancestry and other sources of potential heterogeneity (as discussed above).
Merging rare variation.
Single-point analysis of lowfrequency and rare variants requires hundreds of thousands of individuals in order to detect weak effect sizes. Several approaches for the aggregate analysis of multiple low-frequency or rare variants across a locus that may exhibit heterogeneity have been proposed [95] [96] [97] [98] [99] [100] [101] [102] . Locusbased methods that incorporate variant quality scores available from next-generation sequencing data using a regression-based collapsing approach and an allele-matching method have been also proposed 103 . These qualityincorporating approaches are more powerful than their unweighted counterparts, when the causal variants are of high quality 103 . A sequencing kernel association test (SKAT) seems to outperform previously proposed collapsing methods 104 when a large fraction of the variants in a region are non-causal or the effects of causal variants are in different directions. Collapsing methods seem to be more powerful when most variants in a region are causal, and the effects are in the same direction. Of course, further studies are needed to address power issues, given that few true-positive associations with rare variants have been identified so far. SKAT-O is another interesting unified approach with application in small case-control sequencing studies; it maximizes power by adaptively using the data to combine optimally the burden test and non-burden sequence kernel tests 105 . Besides the known approaches for singlevariant tests, such as the typical logistic Wald test, other exact approaches could be applied, such as the Firth-bias-corrected likelihood ratio test 106 . Most of the methods described above provide a P value or a test statistic as a result for a locus-based association, and these can easily be combined in a meta-analysis when more than one data set is available, as described above. Software has been developed for
Box 3 | Statistical properties of common GWAS meta-analysis approaches
The simplest genome-wide association study (GWAS) meta-analysis approach is to combine P values using Fisher's method. The formula for the statistic is
where P i is the P value for the i th study, and k is the number of studies in the meta-analysis. Under the null hypothesis, X 2 follows a χ 2 distribution with 2k degrees of freedom. The Z scores meta-analysis can be implemented using the equation
where w i is the square root of sample size of the i th study and
where Φ is the standard normal cumulative distribution function. For fixed effects models, inverse variance weighting is widely used. The weighted average of the effect sizes can be calculated as
where θ i is the i th study normalized effect (for example, logarithm of odds ratio or β-coefficient for a logistic regression for a binary phenotype or mean difference or standardized mean difference for a continuous phenotype), and w i is the reciprocal of the estimated variance of the effect study. The random effects model incorporates the between-study variance of heterogeneity, and therefore the weight for the random effects model is calculated as
and Q is Cochran's Q statistic, which is given by
Another popular heterogeneity metric, I 2 , is given by 100 * (Q -(k -1))
The multivariate meta-analysis approaches are based on the calculation of a variance-covariance matrix for the correlated phenotypes or the single-nucleotide polymorphisms in linkage disequilibrium that will allow the calculation of the marginal effects. In cross-phenotype meta-analysis, the developed statistic measures the likelihood of the null hypothesis, given the data. The test is asymptotically distributed as χ df 2 = 1.
Asymptotic assumptions
When the sample size in a data set grows indefinitely, then the distribution of the estimators becomes approximately normal.
× tables
A 2 × 2 table that describes the cross-classification of data that are divided into two groups with two categories in each.
Collapsing approach
Statistical methods for association analysis in which multiple low-frequency or rare variants are collapsing into a single locus.
Lambda inflation factor
A metric used in genetic association studies to correct for spurious associations (which may arise owing to population stratification) by estimating the extent of inflation in the statistical evidence and appropriately down-weighting this inflation.
the meta-analysis of rare variants (such as MetaSKAT, SKAT-O and Rare-METAL). However, it has been shown that meta-analyses based on P values or test statistics for rare variants lose important information. To retain full efficiency, the test can be reformulated using summary statistics from each cohort on both the pervariant score test and the genotype covariance matrix 107 . The individual-variant test statistics are routinely shared for meta-analysis in GWASs anyhow, and the genotype covariance matrix contains no information about genotype-phenotype associations. Thus, data sharing for these quantities should be no more difficult to arrange than in GWASs.
Another important issue to consider is that for rare variants, the identity of the carriers and their privacy may be jeopardized. A method has been developed (MetaSeq) for conducting the meta-analysis in which privacy is maintained through cryptographic means 108 .
Genome-wide significance thresholds for sequencing.
With the inclusion of low-frequency and rare variants from the 1000 Genomes Project imputations and sequencing efforts, in which up to ~50 million markers may be typed, the number of the independent loci under study will be significantly larger than the 1 million markers estimated for GWASs. Therefore, it may be argued that an even more stringent threshold, compared to the typical 5 × 10 −8 , may be required to secure robust findings that will be considered replicated. Additional studies are needed to indicate the optimal threshold. This threshold may depend on sample size, asymptotical properties of the tests, number of low-frequency variants known and other factors.
Issues related to data sources Publicly available data. The benefits of data sharing are obvious. The National Center for Biotechnology Information has created a public repository (called dbGaP) for individual-level phenotype, exposure, genotype and sequence data and the associations between them 109 . Moreover, several funders in Europe and the United States promote sharing of summary data from already published GWASs or meta-analyses of GWASs. This facilitates a wide range of secondary research, both methodological and applied, by investigators who can access these data. There is evidence that participants are in favour of providing a re-consent for submission of their data to dbGaP 110 .
Meta-analyses of meta-analyses. For some phenotypes of interest, several independent or partially overlapping consortia may exist, such as those that are funded by different mechanisms and that are assembled by different initiatives. The successful cooperation between different consortia will allow for mega-analyses, which can include both previously published data and data from meta-analyses that are conducted prospectively. This will significantly increase the power to detect weak signals, especially for low-frequency and rare variants. Consortia studying anthropometric traits such as body mass index have now accumulated almost a quarter of a million participants 111 , and this number is expected to increase markedly in the near future as it has been shown that meta-analysis sample size requirements increase steeply when small genetic effects are considered 4 . Big data in terms of sample sizes may be merged from existing and emerging research teams, consortia, biobanks and other population-level efforts.
The impressive increase in the numbers of included participants may result in an artificial increase of the lambda inflation factor, in many cases with values >2, thus reducing the novel variants assessed in the discovery effort if a genomic control for the observed value is taken in account. Approaches that correct for this inflated lambda and that are based on mixed models are being developed, such as EMMAX 112 . Furthermore, in such efforts, the researchers should always be cautious when they combine data with different sequencing depths and from different platforms. Given that expectations for finding many low-frequency and rare variants with large effects have not been validated in sequencing studies to date, meta-analytical methods will probably continue to be the key approach taken towards exploring further a genetic architecture that is characterized mostly by small effects.
Conclusions and future directions
Multiple methods have been developed for the metaanalysis of available genome-wide data improving our understanding of complex diseases and explaining part of the missing heritability that we were not able to identify using simple association metrics. Merging of existing research teams and consortia may further allow for the identification of novel variants and represent a significant advance in our understanding of genetic susceptibility. iGOGS, a recent example of such a collaborative effort including five consortia studying hormone-mediated cancers, revealed 74 new susceptibility loci for these cancers [113] [114] [115] [116] [117] . Such multi-consortium efforts may become a necessity in the future to identify more low-frequency and rare variants with small or even moderate effects. More empirical and simulation studies are needed to assess the advantages and disadvantages of some of the proposed techniques that were presented here and to delineate their optimal application and interpretation of the results that they produce.
